PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12679132-8 2003 Although argatroban (0.1-0.2 mg/kg/h) did not significantly prolong the aPTT and bleeding time (BT) as compared with control, it significantly accelerated thrombolysis by t-PA at these doses of lower bleeding risk. argatroban 9-19 plasminogen activator, tissue type Homo sapiens 171-175 12679132-7 2003 Argatroban (0.1-0.3 mg/kg/h) significantly accelerated thrombolysis by t-PA in both a dose- and time-dependent fashion. argatroban 0-10 plasminogen activator, tissue type Homo sapiens 71-75 12679132-9 2003 Argatroban (0.3 mg/kg/h) significantly enhanced thrombolysis by t-PA, while UFH (12.5 anti-XaU/kg/h) attenuated it again, despite equivalent prolongation of the aPTT and BT. argatroban 0-10 plasminogen activator, tissue type Homo sapiens 64-68 12679132-10 2003 We conclude that argatroban seems to be a more efficient and safer anticoagulant than UFH for the prevention of thrombus formation and acceleration of t-PA-induced thrombolysis. argatroban 17-27 plasminogen activator, tissue type Homo sapiens 151-155 25610642-6 2014 Argatroban is a direct thrombin inhibitor used as an adjunct to intravenous tPA and showed higher rates of complete recanalisation in the ARTTS study with further studies which are now ongoing. argatroban 0-10 plasminogen activator, tissue type Homo sapiens 76-79 28507269-1 2017 BACKGROUND AND PURPOSE: We conducted a randomized exploratory study to assess safety and the probability of a favorable outcome with adjunctive argatroban, a direct thrombin-inhibitor, administered to recombinant tissue-type plasminogen activator (r-tPA)-treated ischemic stroke patients. argatroban 144-154 plasminogen activator, tissue type Homo sapiens 213-246 22223235-1 2012 BACKGROUND AND PURPOSE: Argatroban is a direct thrombin inhibitor that safely augments recanalization achieved by tissue-type plasminogen activator (tPA) in animal stroke models. argatroban 24-34 plasminogen activator, tissue type Homo sapiens 114-147